CD19 and neoplasm: High tumor burden, a higher concentration of CD19 cells in the bone marrow, pretreatment thrombocytopenia and high CAR T-cell were found to be risk factors for CRS in a study of 133 patients with R/R CD19+ B-cell malignancies who received lymphodepleting chemotherapy followed by CD19 CAR T-cells [34].